- About About
Medical Patient Resources Becoming a State-Authorized Patient Talking to your doctor Which conditions qualify? The Medical Cannabis Patient’s Guide for U.S. Travel Patient's Guide to CBD Patient's Guide to Medical Cannabis Guide to Using Medical Cannabis Condition-based Booklets Growing Cannabis Cannabis Tincture, Salve, Butter and Oil Recipes Leaf411 Affordability Program Tracking Treatment & Gathering Data with Releaf App Medical Professional Resources CME for Medical Professionals Cannabis Safety Medical Cannabis Research
- Legal Legal
Advocacy ASA Chapters Start an ASA Chapter Take Action Campaigns No Patient Left Behind End Pain, Not Lives Vote Medical Marijuana Medical Cannabis Advocate's Training Center Resources for Tabling and Lobby Days Strategic Planning Civics 101 Strategic Messaging Citizen Lobbying Participating in Implementation Movement Building Organizing a Demonstration Organizing Turnout for Civic Meetings Public Speaking Media 101 Patient's History of Medical Cannabis
- News News
Policy Model Federal Legislation Download Ending The Federal Conflict Public Comments by ASA Industry Standards Guide to Regulating Industry Standards Reports 2020 State of the States Medical Cannabis Access for Pain Treatment Medical Cannabis in America Recognizing Science using the Data Quality Act Fact Sheet on ASA's Data Quality Act Petition to HHS Data Quality Act Briefs ASA Data Quality Act petition to HHS Information on Lawyers and Named Patients in the Data Quality Act Lawsuit
- Join Join
Washington, D.C. - Americans for Safe Access (ASA), the leading advocacy organization dedicated to ensuring safe and legal access to cannabis (marijuana) for therapeutic use and research, and Aurelius Data, Inc.(AD), the premier patient perception big data company, and announced a bold new partnership to gather and analyze millions of data points from cannabis patients.
ASA and AD both recognize that while science has made significant strides in cannabis research, there is still a significant gap in education for providers and patients. With the partnership between ASA and AD, the data gathered and analyzed will advance the role of patient use and perception to the forefront of research. Combining that knowledge with chemical product analysis, patient perceived effectiveness, efficacy, form factor, and mechanisms of action (methods of administration) will yield a much-needed educational resource for patients and caregivers, providers, and the industry.
As stated by Dr. Amy Abernathy, the Acting CIO of the Federal Drug Administration, on May 31st of this year, “Systematic studies are needed. It sounds like a number of studies are available or underway. We also wonder if real-world evidence derived from electronic health records, personal monitors, administrative data, etc. can be used to address critical questions in this space.”
Through this joint patient-first initiative, ASA and AD seek to develop a research platform that creates a culture of transparency, integrity and education through data. Aurelius Data’s proprietary AURA platform and analysis tools will compile the use, perception and biometric data of consumers, for which conditions the products are being used and then matching that data with the product’s chemical analyses, and quality information. The insights generated from the platform will be available to users through the AURA mobile application, along with a community offering product education, support and best practices. #SafeAccess
“ASA is excited to be partnering with Aurelius Data, who shares a patient-first mission,” said Debbie Churgai, Interim Director of ASA. “Creating a patient focused community through the AURA platform gives our subscribers a way to connect and discover what regimens are working for other patients, offering an opportunity for real results and lasting change through research.” #MedicalCannabis, #CannabisAdvocacy
"We are so fortunate that ASA recognizes that this partnership allows us to be stronger together and to support a goal that is dear to all of us—to create trust and consistency for patients, and provide a real pathway to effective, standardized treatments," said Julie Armstrong, CEO of Aurelius Data, Inc. #AureliusData
"The Moonshot is to let the data lead the way to identifying novel approaches to treatment, new therapies and outcomes; All without the bias of marketing and advertising, and without the influence of sources who don’t have the patient’s best outcomes as a focus. We recognize our responsibility to the subscribership of ASA and seek to honor this collaboration through providing fresh insights and a value-added community through our AURA platform”, said Armstrong. #BeyondTheStrain
"In that spirit, we're very enthusiastic about the potential of this groundbreaking partnership to drive solutions and improve outcomes for cannabis patients and consumers everywhere," said Churgai.
Americans for Safe Access
The mission of Americans for Safe Access (ASA) is to ensure safe and legal access to cannabis (marijuana) for therapeutic use and research.
ASA was founded in 2002 as a vehicle for patients to advocate for the acceptance of cannabis as medicine. With over 100,000 advocates in all 50 states, ASA is the largest national member-based organization of patients, medical professionals, scientists and concerned citizens promoting safe and legal access to cannabis for therapeutic use and research. ASA works to overcome political, social and legal barriers by creating policies that improve access to medical cannabis for patients and researchers through legislation, education, litigation, research, grassroots empowerment, advocacy and services for patients, governments, medical professionals, and medical cannabis providers.
Aurelius Data, Inc
Aurelius Data, Inc. (AD) is a patient use and perception focused big data company. We deliver insights from analyzing the intersection of science, user perception, product use, chemical analysis, and the users’ reported medical condition and symptom resolution.
Our mission is to put the patient first, by increasing confidence and understanding, drive product development, boost customer retention, reveal cutting edge IP discoveries, and provide immediate, tangible value to every user. Our anonymously gathered data follows HIPPA compliance and immediately benefits the user through a continuous feedback loop of user input, product recommendations and community connection. Our vision is to go beyond the Strain and create a reliable product use and efficacy reference for cannabis users.
Reenal Doshi, Director of Communications and Outreach, Americans for Safe Access
[email protected], (202) 857-4272 x. 4
Jim Bachand, Business Advisor, Aurelius Data, Inc.
[email protected], (501) 420-4206